Skip to main content

GenoMed Applies for Amex Listing as Nasdaq OTC Plan Idles

NEW YORK, July 6 (GenomeWeb News) - GenoMed plans to move from the Pink Sheets over-the-counter market to a listing on the American Stock Exchange.


The company said today that it expects to hear from Amex about the status of its application within six to eight weeks. GenoMed's stock is currently traded on the Pink Sheets under the ticker symbol GMED.


In November 2002, GenoMed announced plans to trade on the Nasdaq over-the-counter bulletin board. David Moskowitz, CEO and chief medical officer of the company, told GenomeWeb News today that changes in accounting rules and other factors led to a number of delays in the approval process. "We never got an official denial, but we certainly didn't get an approval either," he said.


Moskowitz said the company has a good chance of meeting the primary requirement for trading on Amex -- a market capitalization of $50 million. The company has around 200 million shares outstanding, and Moskowitz said he is confident the company can hit and maintain a $0.25 share price to reach the $50 million market cap milestone.


GenoMed's stock was trading at $0.185 as of 12:30 EDT today, after opening at $0.16.


Many brokers avoid Pink Sheet stocks, Moskowitz said, so a move to Amex is expected to increase investor confidence and improve the company's liquidity.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.